Preprint Review Version 1 This version is not peer-reviewed

Uncovering the Significance of CBX3 as an up-and-coming Biomarker in Cardiovascular Health

Version 1 : Received: 1 October 2024 / Approved: 1 October 2024 / Online: 1 October 2024 (13:23:09 CEST)

How to cite: Wahab, M. A.; Del Gaudio, N.; Gargiulo, B.; Quagliariello, V.; Maurea, N.; Grieco, M.; Nebbioso, A.; Altucci, L.; Conte, M. Uncovering the Significance of CBX3 as an up-and-coming Biomarker in Cardiovascular Health. Preprints 2024, 2024100069. https://doi.org/10.20944/preprints202410.0069.v1 Wahab, M. A.; Del Gaudio, N.; Gargiulo, B.; Quagliariello, V.; Maurea, N.; Grieco, M.; Nebbioso, A.; Altucci, L.; Conte, M. Uncovering the Significance of CBX3 as an up-and-coming Biomarker in Cardiovascular Health. Preprints 2024, 2024100069. https://doi.org/10.20944/preprints202410.0069.v1

Abstract

Cardiovascular disease (CVD) is the primary cause of mortality globally with a multifactorial etiology that involves epigenetics. Chromobox 3 (CBX3), the major isoform of heterochromatin protein 1, is involved in intricate epigenetic mechanisms affecting congestive heart failure. In patients with CVD affected by lung cancer risk, CBX3 exerts a sophisticated mechanism of action, suppressing the proliferation, migration, and formation of neointima in vascular smooth muscle cells (VSMCs) by affecting the Notch3 pathway, indicating a potential protective function against vascular remodeling and atherosclerosis. However, the broader impact of CBX3 on endothelial function, as well as its effects on monocyte/macrophage and lymphocyte infiltration and function within the arterial wall, remain poorly understood. Since very little is known so far, more definite research would be needed to reveal the fine mechanisms of CBX3 action, along with its relationship in molecular processes and prospects as a biomarker. Specifically, CBX3 biological features could be examined to gain a greater insight into CVD risks. This review outlines the role of CBX3 in mechanisms associated with CVD and feasibility for optimizing pre-existing therapy and developing new therapeutic strategies based on personalized medi-cine.

Keywords

CBX3; cardiovascular disease; epigenetics; vascular smooth muscle cells; vascular remodeling; inflammation; pathway; chromatin; treatment(s)

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.